Investors

Explore how Hikma’s diversified portfolio, operational excellence, and global reach delivers value for investors

Hikma released its financial results for the year ended 31 December 2025 on Thursday 26 February 2026.
Latest news

Newsroom

All news stories
New

Hikma launches Fidaxomicin Tablets in the US

Press Release, Product
New

Hikma launches Deflazacort Tablets in the US

Press Release, Product

Inspired at Hikma: Building partnerships for growth and to meet patient needs. Meet Lama Shatara, Sr. Director, Business...

Story, Life at Hikma

Hikma appoints Rebecca Hall as Chief Financial Officer

Press Release, Corporate

Hikma R&D Investor Spotlight Series

Press Release, Corporate

Hikma launches Glucentra® as the first generic semaglutide available to patients in Saudi Arabia

Press Release, Product

R&D at Hikma | Meet Dima Freihat, helping bring medicines from development to manufacturing

Story, Life at Hikma

Empowered at Hikma | Meet Ana Catarina Costa, Sr. Manager, Regulatory Affairs, Hikma Portugal

Story, Life at Hikma

Hikma advances its epinephrine nasal spray with multi-market regulatory filings

Press Release, Product

Important Correction of Drug Information

Press Release, Product
Sign up here if you would like to receive email alerts with our latest results, regulatory news, and business updates.
Stay informed